March 11, 2013 / 6:28 PM / in 5 years

Aeterna Zentaris to stop late-stage cancer drug trial, shares fall

(Reuters) - Canadian drugmaker Aeterna Zentaris Inc said it would discontinue a late-stage trial of a cancer drug after an independent data safety monitoring committee said the drug was unlikely to help increase patient survival.

Shares of the company fell as much as 29 percent to C$1.89 on Monday on the Toronto Stock Exchange.

The committee recommended that patient enrollment be stopped and the study discontinued for perifosine, the company said in a statement.

The drug is being studied to treat multiple myeloma, a cancer that starts in plasma cells in bone marrow and disrupts the production of normal blood cells.

The U.S. Food & Drug Administration granted perifosine an orphan-drug designation in September 2009 as well as a fast-track designation in December 2009.

The late-stage trial compared the efficacy and safety of perifosine to a placebo when combined with bortezomib and dexamethasone in patients with multiple myeloma.

The committee also said it was highly unlikely that the study would achieve a significant difference in its primary endpoint and progression free survival, or increasing survival of patients without the cancer worsening.

Reporting by Shounak Dasgupta in Bangalore; Editing by Roshni Menon

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below